Article information
En este artículo se resumen las principales características de los fármacos utilizados para tratar las infecciones virales, exceptuando la infección por el virus de la inmunodeficiencia humana (VIH). Se tratan los antivirales activos frente al virus del herpes, citomegalovirus (CMV), virus de la hepatitis B y C (VHB y VHC) y virus respiratorios como el de la gripe y el virus respiratorio sincitial (VRS). Se indica su dosificación en función de la indicación, el ajuste de dosis en caso de insuficiencia renal o hepática, sus características farmacocinéticas más relevantes, así como sus principales efectos secundarios e interacciones.
Palabras clave:
Antivirales
Herpesvirus
Citomegalovirus
Virus respiratorios
Hepatitis B
Hepatitis C
Influenza
Virus respiratorio sincitial
Characteristics of antiviral drugs. This article summarizes the principal characteristics of the drugs used to treat viral infections, with the exception of human immunodeficiency virus infection. It includes antiviral agents active against herpes virus, cytomegalovirus, hepatitis B and C virus, and respiratory viruses, such as influenza and respiratory syncytial virus. Dosage according to the indication, dose adjustment in the case of renal or hepatic insufficiency, significant pharmacokinetic characteristics, and the main adverse effects and interactions are described
Key words:
Antiviral agents
Herpesvirus
Cytomegalovirus
Respiratory viruses
Hepatitis B
Hepatitis C
Influenza
Respiratory syncytial virus
Full text is only aviable in PDF
Bibliografía
[1.]
S.M. Waugh, D. Pillay, D. Carrington, W.F. Carman.
Antiviral prophylaxis and treatment (excluding HIV therapy).
J Clin Virol, 25 (2002), pp. 241-266
[2.]
Sweetman S, editor. Martindale: The Complete Drug Reference. London: Pharmaceutical Press, Electronic version, MICROMEDEX, Greenwood Village, Colorado, (Edition expires [6/2003])
[3.]
Hutchison TA, Shahan DR, editors. DRUGDEX? System. MICROMEDEX, Greenwood Village, Colorado (Edition expires [6/2003]).
[4.]
J. Mensa, J.M. Gatell, M.T. Jiménez de Anta, G. Prats.
Masson, (2002),
[5.]
Anónimo. Fármacos para las infecciones virales (excepto VIH).
Med Lett Drugs Ther, 24 (2002), pp. 19-26
[6.]
L.F. Villa, C. Esteban, T. Requena, M. Sanjurjo, I. Fernández, G. De la Sierra, et al.
Adis Internacional, (2003),
[7.]
E. Carreras, S. Brunet, J.J. Ortega, M. Rovira, J. Sierra, A. Urbano-Ispizua.
Antares, (2000),
[8.]
A.F. Nikkels, G.E. Pierard.
Treatment of mucocutaneous presentations of herpes simplex virus infections.
Am J Clin Dermatol, 3 (2002), pp. 475-487
[9.]
R.J. Whitley.
Herpes simplex virus infection.
Semin Pediatr Infect Dis, 13 (2002), pp. 6-11
[10.]
A.M. Enright, C.G. Prober.
Neonatal herpes infection: Diagnosis, treatment and prevention.
Semin Neonatol, 7 (2002), pp. 283-291
[11.]
F. Cainelli, S. Vento.
Infections and solid organ transplant rejection: A cause-and-effect relationship?.
Lancet Infect Dis, 2 (2002), pp. 539-549
[12.]
P.D. Griffiths.
Tomorrow’s challenges for herpesvirus management: Potential applications of valacyclovir.
J Infect Dis, 186 (2002), pp. 131-137
[13.]
A. Sauerbrei, P. Wutzler.
Neonatal varicella.
J Perinatol, 21 (2001), pp. 545-549
[14.]
D.E. Dwyer, A.L. Cunningham.
Herpes simplex and varicella-zoster virus infections.
Med J Aust, 177 (2002), pp. 267-273
[15.]
M.D. Khare.
Human herpesvirus 6: Its impact and influence on infectious diseases and their management.
Expert Opin Pharmacother, 2 (2001), pp. 213-221
[16.]
T.H. Bacon, M.J. Levin, J.J. Leary, R.T. Sarisky, D. Sutton.
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy.
Clin Microbiol Rev, 16 (2003), pp. 114-128
[17.]
J.P. Squifflet, C. Legendre.
The economic value of valacyclovir prophylaxis in transplantation.
J Infect Dis, 186 (2002), pp. 116-122
[18.]
D.A. Baker.
Valacyclovir in the treatment of genital herpes and herpes zoster.
Expert Opin Pharmacother, 3 (2002), pp. 51-58
[19.]
J. Balzarini, C. McGuigan.
Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides.
Biochim Biophys Acta, 1587 (2002), pp. 287-295
[20.]
Z. Vancikova, P. Dvorak.
Cytomegalovirus infection in immunocompetent and immunocompromised individuals–a review.
Curr Drug Targets Immune Endocr Metabol Disord, 1 (2001), pp. 179-187
[21.]
S.W. Chou.
Cytomegalovirus drug resistance and clinical implications.
Transpl Infect Dis, 3 (2001), pp. 20-24
[22.]
V.C. Emery.
Progress in understanding cytomegalovirus drug resistance.
J Clin Virol, 21 (2001), pp. 223-228
[24.]
J.M. Cocohoba, I.R. McNicholl.
Valganciclovir: An advance in cytomegalovirus therapeutics.
Ann Pharmacother, 36 (2002), pp. 1075-1079
[25.]
E. De Clercq.
Cidofovir in the treatment of poxvirus infections.
Antiviral Res, 55 (2002), pp. 1-13
[26.]
E. De Clercq.
Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.
Clin Microbiol Rev, 14 (2001), pp. 382-397
[27.]
V.C. Emery, A.F. Hassan-Walker.
Focus on new drugs in development against human cytomegalovirus.
Drugs, 62 (2002), pp. 1853-1858
[28.]
M. Buti, R. Esteban.
Adefovir dipivoxil.
Drugs Today (Barc), 39 (2003), pp. 127-135
[29.]
J.M. Sánchez Tapias.
Tratamiento farmacológico de las hepatitis crónicas víricas.
El Farmacéutico Hospitales, 137 (2002), pp. 20-44
[30.]
J. Feld, S. Locarnini.
Antiviral therapy for hepatitis B virus infections: New targets and technical challenges.
J Clin Virol, 25 (2002), pp. 267-283
[31.]
S.S. Huang, R.L. Skolasky, G.J. Dal Pan.
Royal W 3rd, McArthur JC. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: An observational study.
J Neurovirol, 4 (1998), pp. 324-332
[32.]
A. Rivkina, S. Rybalov.
Chronic hepatitis B: Current and future treatment options.
Pharmacotherapy, 22 (2002), pp. 721-737
[33.]
A.M. Di Bisceglie, J.H. Hoofnagle.
Optimal therapy of hepatitis C.
Hepatology, 36 (2002), pp. 121-127
[34.]
S. Pol, A. Vallet-Pichard, H. Fontaine, P. Lebray.
HCV infection and hemodialysis.
Semin Nephrol, 22 (2002), pp. 331-339
[35.]
K. Rajender Reddy, M.W. Modi, S. Pedder.
Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.
Adv Drug Deliv Rev, 54 (2002), pp. 571-586
[36.]
B.A. Luxon, M. Grace, D. Brassard, R. Bordens.
Pegylated interferons for the treatment of chronic hepatitis C infection.
Clin Ther, 24 (2002), pp. 1363-1383
[37.]
G. Chander, M.S. Sulkowski, M.W. Jenckes, M.S. Torbenson, H.F. Herlong, E.B. Bass, et al.
Treatment of chronic hepatitis C: A systematic review.
Hepatology, 36 (2002), pp. 135-144
[38.]
J. Watson.
Prospects for hepatitis C virus therapeutics: Levovirin and viramidine as improved derivatives of ribavirin.
Curr Opin Investig Drugs, 3 (2002), pp. 680-683
[39.]
J.G. McHutchison, K. Patel.
Future therapy of hepatitis C.
Hepatology, 36 (2002), pp. 245-252
[40.]
G. Stiver.
The treatment of influenza with antiviral drugs.
Can Med Assoc J, 168 (2003), pp. 49-56
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
